KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Biotech

LegoChem Biosciences Signs 496.3 Bln Won Licensing Deal with UK Iksuda

 1,451 total views,  1 views today

James Jung by James Jung
PUBLISHED: April 15, 2020 UPDATED: April 18, 2020
in Biotech, Iksuda Therapeutics, LegoChem Biosciences, Medical industry, South Korea
0
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.

LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.

LegoChem Biosciences Inc. announced it signed a 496.3 billion won ($405 million) worth agreement on licensing out its antibody-drug conjugate (ADC) technology to Iksuda Therapeutics, a U.K.-based biotech company.

The South Korean biotech company licensed out its ADC linker/toxin technology named ConjuAll to Iskuda. The deal allows the British firm to exclusive rights to develop and commercialize three ADC-based cancer therapies internationally.

ADC links specific antibodies to antigens present on tumor cells using anticancer chemical drugs through a linker. LegoChem’s ConjuAll is an ADC-based technology that uses proprietary linker chemistry mixed with site-specific enzymatic conjugation.

Iksuda Therapeutics was founded in 2012 by renowned ADC experts.

Meanwhile, LegoChem could still license out its ConjuAll platform to other companies past the three arranged target therapies.

Licensing Agreement

LegoChem also signed a similar license agreement with Japan-based Takeda Pharmaceutical for ConjuAll last year. It received 8.9 billion won ($7.25 million) in upfront and near-term milestone payments. LegoChem is also eligible to receive development, regulatory and commercial milestone payments of up to 496 billion won ($404 million).

Under the agreement, LegoChem would receive 496.3 billion won ($405 million) upfront and milestone payments. The company would also receive the right to additional royalties on sales of related products in the future.

Based on predetermined ratios, LegoChem is eligible to receive a part of Iksuda’s out-licensing profit if Iksuda licenses out ConjuAll during its drug development process to a third party.

LegoChem CEO Kim Yong-zu said that Iksuda’s world-leading competence in developing ADC could send their technology to the clinical trial stage quicker than any company.

Iksuda CEO and co-founder Dr. David Simpson said that the company would take advantage of LegoChem’s excellent linker and next-generation PBD toxin to enter the clinical stage as fast as possible.

LegoChem reported a 16 billion won ($13 million) revenue last year. The company has signed six licensing agreements, including Iksuda’s deal, with a combined value of 1.7 trillion won ($1.39 billion).

What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: 496.3 billion wonADCbiotechcancer treatmentclinical stageIksudaLegoChemlicensing dealSouth Korea news

Related Posts

Samsung headquarters
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
South Korea

Korea’s top 100 companies’ economic contribution soar by 20%  in 9 years

July 20, 2022
South Korea curbs tech leaks to foreign countries
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
South Korea

South Korea curbs tech leaks to foreign countries

February 8, 2022
Hyundai Rotem set to provide upgraded army tank variants to South Korea
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
South Korea

Hyundai Rotem set to provide upgraded army tank variants to South Korea

February 2, 2022
S.Korea will track COVID-19 cases with AI-powered facial recognition from January
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
South Korea

S.Korea will track COVID-19 cases with AI-powered facial recognition from January

December 14, 2021
South Korea sets site engineering standards for big tech firms
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
Google

South Korea sets site engineering standards for big tech firms

December 9, 2021
National AI complex project starts in South Korea: New AI hub in making
LegoChem Biosciences Inc. signed a 496.3 billion won agreement on licensing out its antibody-drug conjugate tech to UK-based Iksuda Therapeutics.
South Korea

National AI complex project starts in South Korea: New AI hub in making

November 25, 2021
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • Top Eight Promising EdTech Startup Companies in South Korea

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • Korean tech giants to focus on future innovations & sustainability actions at CES 2023 

    0 shares
    Share 0 Tweet 0
  • Top Nine Mobile MMORPG in South Korea for 2020

    0 shares
    Share 0 Tweet 0
  • World’s First 5G Robot Café has a Seoul Opening

    0 shares
    Share 0 Tweet 0
  • Top 10 Must-Have Korean Apps You Need When Visiting in Korea

    0 shares
    Share 0 Tweet 0
  • South Korea Improves Digital New Deal with the Data Dam Project

    0 shares
    Share 0 Tweet 0
  • Coway Changes Name After Netmarble’s Aquisition

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2022 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2022 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |